SAN DIEGO – Neurocrine (NASDAQ:NBIX) Biosciences, Inc. (NASDAQ:NBIX) has commenced a Phase 2 clinical trial to assess the efficacy and safety of its experimental drug NBI-1070770 in adults with major depressive disorder (MDD), the company announced today. The trial marks a significant step in the development of NBI-1070770, a negative allosteric modulator targeting the NMDA NR2B receptor, which is implicated in various neurological disorders.
The randomized, double-blind, placebo-controlled study will involve approximately 72 participants across multiple centers in the United States. Its primary goal is to determine the impact of NBI-1070770 on symptoms of depression, as measured by the Montgomery-Åsberg Depression Rating Scale. This follows the acquisition of development and commercialization rights to NBI-1070770 from Takeda Pharmaceutical Company (NYSE:TAK), Ltd.
Neurocrine Biosciences, a biopharmaceutical company focusing on neurological and endocrine-related diseases, has a history of developing FDA-approved treatments for conditions such as tardive dyskinesia and chorea associated with Huntington's disease. The company's pipeline includes various compounds in mid- to late-phase clinical development.
Chief Medical Officer Eiry W. Roberts, M.D., expressed optimism about the potential of NBI-1070770, citing the compound's selectivity for the NMDA NR2B receptor and its promising Phase 1 trial results. The company's mission is to develop treatments for people with significant unmet medical needs, particularly in the neurological and neuropsychiatric domains.
This announcement is based on a press release statement from Neurocrine Biosciences. For additional details about the Phase 2 study (NBI-1070770-MDD2029), interested parties can refer to Clinicaltrials.gov.
InvestingPro Insights
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is making strides in the biopharmaceutical industry with its latest clinical trial, and investors are keeping a close eye on the company's financial health and stock performance. According to InvestingPro data, Neurocrine Biosciences boasts a market capitalization of $13.71 billion, reflecting its significant presence in the sector. The company's price-to-earnings (P/E) ratio stands at 53.49, with an adjusted P/E ratio for the last twelve months as of Q4 2023 at a lower 40.2, indicating a more favorable valuation when considering its earnings growth.
With a robust revenue growth of 26.76% over the last twelve months, Neurocrine Biosciences demonstrates its ability to expand its financial base, which is crucial for funding ongoing research and development activities such as the Phase 2 trial for NBI-1070770. This is further supported by a solid operating income margin of 20.92%, showcasing the company's efficiency in translating revenue into operational profit.
InvestingPro Tips for Neurocrine Biosciences highlight that the company is expected to grow its net income this year and is trading at a low P/E ratio relative to near-term earnings growth. These insights suggest that the stock may be an attractive option for investors looking for growth potential. Notably, the company has been profitable over the last twelve months and analysts predict it will continue to be profitable this year. Additionally, the stock is trading near its 52-week high, at 92.84% of this peak value, showing strong market confidence.
For investors seeking more in-depth analysis and additional InvestingPro Tips for Neurocrine Biosciences, they can find 14 more tips on InvestingPro. To further enhance their experience, users can take advantage of an exclusive offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.